- Home
- CHRS vs EPM Comparison
CHRS vs EPM Comparison
Compare CHRS & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | EPM |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.0M | 158.2M |
| IPO Year | 2014 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CHRS | EPM |
|---|---|---|
| Price | $1.78 | $4.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $5.51 | $4.93 |
| AVG Volume (30 Days) | ★ 1.8M | 384.6K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | ★ 10.76% |
| EPS Growth | ★ 109.88 | N/A |
| EPS | ★ 1.77 | 0.05 |
| Revenue | N/A | ★ $43,229,621.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.63 | N/A |
| P/E Ratio | ★ $0.94 | $88.40 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $3.19 |
| 52 Week High | $2.62 | $5.70 |
Technical Indicators
Market Signals| Indicator | CHRS | EPM |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 62.60 |
| Support Level | $1.55 | $4.38 |
| Resistance Level | $1.89 | $4.63 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 40.00 | 80.14 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.